Aldeyra Therapeutics, Inc. cotiza a 0.90 USD y tiene una capitalización bursátil de $54M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis;…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.09 | $-0.06 | $-0.10 |
| Estimado | $-0.08 | $-0.08 | $-0.12 | $0.16 |
| Sorpresa | — | -12.5% | +50.0% | -162.5% |
| Métrica | ALDX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -76.5% | -40.4% | -36.1% |
| ROA | -47.0% | -32.0% | -15.0% |
| Current Ratio | 2.58 | 2.84 | -0.26 |
| Debt / Equity | 0.35 | 0.28 | +0.07 |